7.91
+1.67%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hainan Shuangcheng Pharmaceuticals Co
Its shares trade on Shenzhen under the ticker 002693.SZ. It has been listed since 8 August 2012. In the fiscal year to 31 December 2025, it reported revenue of CN¥276.8m and net income of CN¥19.0m. At that date it held total assets of CN¥825.8m and shareholders' equity of CN¥412.5m.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemically synthesized peptide drugs. The company is headquartered in Haikou, Hainan. The company went IPO on 2012-08-08. The firm's main products include Jitai (thymalfasin for injection), for the treatment of various types of liver diseases, cancers, geriatric deseases and infectious diseases; thymopentin for infection; somatostatin, for the treatment of severe acute esophageal variceal bleeding and severe acute stomach or for the adjuvant therapy of duodenal ulcer bleeding and diabetic ketoacidosis, as well as other drugs. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Aug 2012
- Employees
- 414
- Website
- shuangchengmed.com ↗
Leadership
Pay as last reported
- Mr. Chengdong WangChairman of the Board, since 2017CN¥331,900
- Ms. Jing BaiVice Chairman of the Board, since 2022
- Mr. Xuguang WangChief Financial OfficerCN¥381,200
- Ms. Haiyan LiChief Human Resource Officer, Deputy General Manager
- Mr. Jianming LiGeneral Manager, Director, since 2013CN¥879,400
- Ms. Xiaofeng YuSecretary of the Board, Deputy General ManagerCN¥378,400
- Mr. Yixiang AiDeputy General Manager
- Ms. Yuan LiDeputy General Manager
- Ms. Rui WangDeputy General Manager, Chief Analysis Officer
- Mr. Shiying WangDeputy General Manager
- Mr. Zhong YaoDeputy General Manager
- Mr. Jianlin YuanDeputy General Manager, since 2010CN¥497,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company engages in the research and development of chemically synthesized peptide drugs.
- It distributes its products in domestic markets and to overseas markets.
- The firm employs 414 full-time employees at its headquarters in Haikou.
Weaknesses
- The source description is treated as untrusted facts.
- Specific financial metrics and revenue figures are not provided.
- Details regarding operational efficiency or cost structures are missing.
Opportunities
- The company can expand its sales of peptide drugs in overseas markets.
- It may develop new treatments for liver diseases and cancers.
- Growth is possible through the adjuvant therapy of duodenal ulcer bleeding.
Threats
- Reliance on untrusted source data poses accuracy risks.
- Competition in the pharmaceutical sector is likely intense.
- Regulatory changes in China could impact production and sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.